[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.170.48. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Cardiology Clinical Guidelines Synopsis
February 2017

Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk

Author Affiliations
  • 1Division of Cardiology, Departments of Preventive Medicine and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Cardiol. 2017;2(2):218-219. doi:10.1001/jamacardio.2016.4640

The Expert Consensus Decision Pathway1 provides clinical workflows for treatment of patients in whom nonstatin medications may be considered in the setting of maximally tolerated statin therapy. The objective was to provide guidance for clinicians in light of new data from randomized clinical trials published since the 2013 guidelines and given approval by the US Food and Drug Administration of PCSK9 inhibitors in 2015. The Expert Consensus Panel addressed 3 questions:

×